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Abstract 
Chondrocytes, the single cell type in adult articular cartilage, have conventionally been 
considered to be non-excitable cells. However, recent evidence suggests that their resting 
membrane potential (RMP) is less negative than that of excitable cells, and they are fully 
equipped with channels that control ion, water, and osmolyte movement across the chondrocyte 
membrane. Among calcium-specific ion channels, members of the voltage-dependent calcium 
channel (VDCC) family are expressed in chondrocytes where they are functionally active. L-
type VDCC inhibitors such as nifedipine and verapamil have contributed to our understanding 
of the roles of these ion channels in chondrogenesis, chondrocyte signalling, and 
mechanotransduction. In this narrative review, we discuss published data indicating that VDCC 
function is vital for chondrocyte health, especially in regulating proliferation and maturation. 
We also highlight the fact that activation of VDCC function appears to accompany various 
inflammatory aspects of osteoarthritis (OA) and, based on in vitro data, the application of 
nifedipine and/or verapamil may be a promising approach for ameliorating OA severity. 
However, very few studies on clinical outcomes are available regarding the influence of 
calcium antagonists, which are used primarily for treating cardiovascular conditions in OA 
patients. This review is intended to stimulate further research on the chondrocyte 
‘channelome’, contribute to the development of novel therapeutic strategies, and facilitate the 
retargeting and repositioning of existing pharmacological agents currently used for other co-
morbidities for the treatment of OA. 
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Abbreviations 
BCP  Basic calcium phosphate 
DHT  Dihydrotestosterone 
ECM  Extracellular matrix 
ET  Endothelin 
GAG  Glycosaminoglycan 
IGF-1  Insulin-like growth factor-1 
MMP  Matrix metalloproteinase 
OA  Osteoarthritis 
PDGF  Platelet-derived growth factor 
PGE2  Prostaglandin E2 
PKC  Protein kinase C 
PLC  Phospholipase C 
PTHrP  Parathyroid hormone related peptide 
RMP  Resting membrane potential 
SLRP  Small leucine-rich proteoglycans 
TGF-  Transforming growth factor  
VDCC  Voltage-dependent calcium channel 
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Introduction 
A thin layer of hyaline articular cartilage covers the articulating bones in most load-
bearing synovial joints in the human body, where it enables frictionless movement and provides 
protection for subchondral bone. Adult cartilage contains a single cell type, the chondrocyte, 
with the main function of maintaining the proper composition of the extracellular matrix 
(ECM), in which they are embedded. The ECM of hyaline cartilage primarily consists of a 
dense and cross-linked meshwork of fibrillar collagens (predominantly type II collagen) and 
other minor collagens (mainly type VI, IX, and XI) that are incorporated in the fibrillar collagen 
network, regulating fibril assembly, organization, and degradation. This matrix is packed with 
large aggregating proteoglycans (e.g., aggrecan) and their constituent glycosaminoglycans 
(GAGs; e.g., chondroitin sulphate, keratan sulphate, hyaluronan, etc.), which possess a net 
negative charge attracting counteracting cations and high quantities of osmotically obliged 
water (approx. 70% of the net weight of ECM) [1]. Small leucine-rich proteoglycans (SLRPs) 
such as decorin, biglycan, and fibromodulin are specialised ECM molecules that contain 
multiple repeats of a leucine-rich structural motif, flanked by cysteine residues. SLRPs also 
modify the deposition and arrangement of fibrillar collagen fibres in the ECM. They also 
interact with cells and soluble growth factors such as transforming growth factor  (TGF-) 
that may affect the proliferation of chondrocytes in addition to modifying the composition of 
the ECM. 
As a unique type of connective tissue, mature articular cartilage is avascular, aneural 
and alymphatic [2]. Chondrocytes are surrounded by a pericellular matrix and are situated in 
cavities called lacunae within the ECM, where they exist in a hypoxic micro-environment [3, 
4] and control ECM turnover and homeostasis in response to mechanical loading [5] despite 
having a rather slow (mainly anaerobic) metabolism. Due to the fact that chondrocytes reside 
within the peculiar milieu of the ECM (which is acidic, hypertonic and hyperosmotic [6-8]), 
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and since their function and differentiation is strongly dependent on intracellular calcium 
homeostasis [9, 10], they deploy a whole range of ion channels to enable ion transport across 
the plasma membrane; the collection of ion channels is referred to as the chondrocyte 
‘channelome’ [11]. Albeit generally considered to be non-excitable cells, chondrocytes and 
chondroprogenitor cells have been reported to express various voltage-dependent potassium 
channels (KV), ATP dependent potassium channels (KATP), large and small conductance 
calcium-activated potassium channels (BK and SK), transient receptor potential channels 
(primarily TRPV1 and TRPV4), purinergic receptors (both P2X and P2Y subfamily members), 
voltage gated and epithelial sodium channels, chloride channels, and also voltage-dependent 
calcium channels (VDCCs) [11-13]. 
 
Physiology and pharmacology of voltage-dependent calcium channels (VDCCs) 
Under physiological conditions, Ca2+ concentration is several thousand times higher in 
the extracellular space than in the cytoplasm. Activation of VDCCs results in rapid elevation 
of intracellular Ca2+ levels and initiates various cellular responses. VDCCs are typically closed 
at resting membrane potentials and their opening requires depolarization. VDCCs, along with 
other structurally similar voltage-gated ion channels such as NaV or KV channels, are tetrameric 
cation channels with four transmembrane domains (I-IV) surrounding a selective central pore 
and typically consist of α1, α2δ, β, and γ subunits. Although the main structural and topological 
features of VDCCs are largely conserved, their physiological and pharmacological properties 
can be very different. The α1 subunit, besides forming the pore, also determines the type of the 
channel; to date, 10 different α1 subunits have been isolated, which can be classified into the 
structurally and functionally related families of CaV1, CaV2, and CaV3 (see Table 1). The other 
ancillary subunits (four α2δ, four β, and eight different γ subunits are known) modulate the 
functional properties of these ion channels. There are five different types of VDCCs; members 
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of the L-type (or “Long Lasting”) group of Ca2+ channels contain one of the CaV1.1, CaV1.2, 
CaV1.3, or CaV1.4 α1 subunits; the N-type (“Neural”) contains CaV2.1; the P/Q-type 
(“Purkinje”) contains CaV2.2; the R-type (“Residual”) contains CaV2.3; and members of the T-
type (“Transient”) group contain CaV3.1, CaV3.2, or CaV3.3 α1 subunits (Table 1) [14, 15]. It 
is of note that the L, N, P/Q and R-type calcium channels are activated at high voltage (HVA), 
while T-type calcium channels are activated at negative resting membrane potential (RMP) 
values and are considered as members of the low voltage-activated (LVA) family [16]. 
Inhibitors such as nifedipine or small peptide toxins from certain spider, snail, or 
scorpion species have contributed to our understanding of the roles of these calcium channels 
in various models. VDCCs are targets of existing drugs for the treatment of various 
cardiovascular diseases and central nervous system disorders. Dihydropyridines, phenyl-
alkylamines, benzodiazepines, and other small molecules are widely used potent L-type 
channel blockers. Nifedipine is a member of the dihydropyridine family of calcium channel 
blocking agents. Its mechanism of action is to inhibit calcium influx, thereby causing, for 
example, smooth muscle cell relaxation and consequent vasodilation. Therefore, nifedipine, 
along with other dihydropyridines such as amlodipine or nicardipine, is a potent and widely 
used anti-hypertensive drug [17]. The phenyl-alkylamine verapamil, another potent calcium 
antagonist, binds to a distinct site on the ion channel and is also widely used as an anti-
hypertensive drug [18]. The L-type channels are sensitive to the neurotoxin calciseptine, in 
addition to the conventional blockers [16]. The main modulators of N-type calcium channels 
are ω-conotoxins; P/Q-type channels are selectively blocked by ω-agatoxins; and the peptide 
neurotoxin SNX-482 is a selective R-type calcium channel inhibitor. To date, no specific 
blockers for T-type Ca2+ channels have been identified [19]. 
 
VDCCs and the effects of nifedipine/verapamil on chondrocytes 
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Whilst the roles of VDCCs in excitable cells such as muscle, nerve, or endocrine cells 
are well established, they act in an even more complex way in non-excitable cells that involves 
regulating enzyme activity or gene expression [19]. Although there is now an accumulating 
body of data demonstrating the presence and function of VDCCs in chondrocytes, their specific 
roles in different models are still not entirely clear. We therefore provide a detailed overview 
of what has been published in the literature, including our own findings, concerning VDCCs 
and the effects of the most frequently applied inhibitors such as nifedipine and verapamil in 
differentiating and adult chondrocytes. 
The first implication that VDCCs might be involved in early steps of chondrogenic 
differentiation was published in 1989 [20]. When nifedipine (40–100 μmol/kg) was 
administered to rabbits per os on day 16 of gestation, a range of digital defects developed in 
the foetuses, including reduction, total absence, or abnormal structure of the distal phalanx of 
the fourth digit on the hind paws. These defects were mainly brought about by disturbed 
chondrogenesis and osteogenesis. It must be added, however, that administration of a drug with 
a different mechanism of action and different targets (i.e., hydralazine that blocks voltage-gated 
potassium channels) resulted in the same outcome, indicating that the effect of nifedipine on 
digit formation in the foetuses was not specific. Indeed, decreased utero-placental blood flow 
caused by excessive hypotension, rather than a direct blockade of the voltage-dependent ion 
channel, was implicated as the most probable mechanism underlying the observed defects in a 
follow-up study [21]. No apparent disturbance of chondrogenesis was observed in embryonic 
chick limb bud-derived micromass cultures at concentrations of nifedipine below 3 × 105 μM. 
Additional, more specifically targeted experiments were carried out subsequently to 
explore the role of VDCCs in chondrocytes. In bovine articular chondrocytes, administration 
of endothelin or platelet-derived growth factor (PDGF) evoked either non-oscillatory Ca2+ 
transients or oscillatory Ca2+ events during single cell Ca2+ recordings, depending on the 
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subpopulation of cells [22]. Ca2+ spiking was not altered in the presence of nifedipine; also, 
depolarization of chondrocytes by high concentrations of K+ did not induce Ca2+ transients and 
the study concluded that VDCCs were not functional in these cells. In contrast, nifedipine 
(administered i.v. at 6 mg/kg/day twice daily) interfered with elongation of long bones in vivo 
in growing rabbits, affecting the epiphyseal growth plate and bone remodelling [23]. This 
observation was supported by in vitro data; treatment of mouse embryonic limb bud-derived 
micromass cultures with nifedipine or verapamil during the early stages of differentiation 
inhibited chondrogenesis, reflecting on an important role of L-type VDCCs during cartilage 
formation [24]. Furthermore, in high-density primary cultures of human articular chondrocytes, 
application of verapamil or nifedipine abrogated the stimulatory effect of prostaglandin E2 
(PGE2) on IGFBP-3, a protein that regulates the bioactivity and bioavailability of insulin-like 
growth factor-1 (IGF-1), an important mediator of chondrocyte metabolism [25]. In a follow-
up study, IGF-1, IGF-2 and insulin all increased cytosolic Ca2+ levels in cultured rabbit articular 
chondrocytes but through different mechanisms; Ca2+ influx mediated by L-type VDCCs was 
involved downstream of IGF-1 and insulin, since verapamil diminished these responses [26].  
In contrast to earlier observations [23], a different study showed that chicken growth 
plate chondrocytes did not express functional L-type VDCCs; whilst administration of high 
concentrations of extracellular K+ evoked large intracellular Ca2+ transients, nifedipine (or 
nitrendipine) was unable to block channel activity, even at 10 times higher concentrations than 
used normally (at 100 μM) [27]. Furthermore, lack of Ca2+ transients evoked by BAY K 8644, 
an agonist that triggers activation and prolonged opening of L-type channels, corroborated the 
above findings. Cd2+, on the other hand, significantly blocked K+-evoked Ca2+ transients, 
indicating that these cells mainly express N-type VDCCs. 
To further elucidate the role of L-type VDCCs in bovine articular chondrocytes, their 
involvement in mediating cartilage ECM gene induction and matrix metalloproteinase (MMP) 
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gene suppression by capacitatively coupled electric field (60 kHz; 20 mV/cm) was investigated 
[28]. Whilst electrical stimulation significantly upregulated aggrecan and collagen type II 
mRNA expression, and at the same time downregulated IL-1β induced MMPs, these were 
completely eliminated by the L-type VDCC blocker verapamil. However, this study did not 
demonstrate downstream pathways that link Ca2+ influx through VDCCs to the regulation of 
matrix genes. 
To put in context the role of L-type VDCCs, a hypothesis was elaborated to explain the 
role of these channels in dihydrotestosterone (DTH) signalling; showing that DHT regulates 
growth plate chondrocytes in a sex-specific manner [29]. Upon binding to its 7-TM domain-
containing plasma membrane receptor, DTH was proposed to initiate the phospholipase C 
(PLC) signalling pathway leading to Ca2+ release from internal Ca2+ stores through activation 
of IP3 signalling; furthermore, Gβγ subunits would induce Ca
2+ influx through L-type VDCCs 
in resting zone growth plate chondrocytes derived from male rats. The increase in cytosolic 
Ca2+ levels, sourced from both Ca2+ release and influx, would eventually activate classic 
protein kinase C (PKC) isoenzymes, leading ultimately to chondrocyte differentiation. 
 
VDCC inhibitors influence proliferation and resting membrane potential (RMP) in 
chondrocytes 
Every living cell is characterised by RMP, the voltage across the plasma membrane, 
which is generated by the activities of different ion channels or transporters with specific ion 
selectivities and permeabilities. As discussed earlier, even though the chondrocyte is a non-
excitable cell type, RMP acts as a key biophysical signal modulating important activities such 
as volume regulation, proliferation, and differentiation [30]. To identify what roles VDCCs 
may play in the regulation of chondrocyte proliferation and RMP, several studies have been 
conducted. The first work in this field revealed that, in high density porcine articular 
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chondrocyte cultures, verapamil stimulated 3H-thymidine uptake both in control conditions and 
following treatment with IGF-1; the stimulatory effect on cell proliferation was accompanied 
by a reduced rate of 35S-incorporation indicative of inhibited GAG secretory processes [31]. In 
contrast, nifedipine appears to have the opposite effect on chondrocyte proliferation; 
application of 10 μM nifedipine completely abolished the enhanced proliferation and 
differentiation of chicken sternum-derived chondrocytes cultured on 3D collagen scaffoldings 
triggered by cyclic mechanical load [32]. To address the apparent contradiction between these 
two results, further experiments were conducted. When the influence of a set of ion channel 
inhibitors was studied on the RMP and proliferation of human chondrocytes isolated form OA 
knee cartilage [33], verapamil reduced the RMP of chondrocytes by 18%; also suggested was 
that the ion channel modulators investigated in this study might influence chondrocyte cell 
proliferation. Subsequent work showed marked suppression of proliferation in human articular 
chondrocytes following longer incubation times with verapamil; however, it must be noted that 
verapamil treatment also caused pronounced cytotoxic effects in these cells [34]. 
To gather further information on the effects of verapamil on the proliferation rate of 
chondrocytes, the influence of verapamil on endochondral ossification using foetal rat 
metatarsal rudiments was studied [35]. Verapamil reduced growth of the rudiments and the 
number of hypertrophic chondrocytes, as well as proliferation, indicating that the function of 
L-type VDCCs is also required for the proliferation of epiphyseal growth plate chondrocytes. 
Our own results showing an almost complete lack of proliferating cells in embryonic chicken 
limb bud-derived micromass cultures treated with nifedipine are in complete agreement with 
these findings [36], indicating an important positive role for VDCCs in regulating the 
proliferation of differentiating chondrocytes. The effects of nifedipine and verapamil on 
chondrocytes are summarised in Table 2. 
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Subunit-specific expression of VDCC: α1 subunits 
In the first study to describe the subunit-specific expression of VDCCs, CaV1.2 L-type 
α1 subunit expression was identified in rat tracheal cartilage using immunohistochemistry [37]. 
Later on, the presence of the α1 subunit protein of VDCCs was confirmed using a non-specific 
pan α1-subunit antibody in mouse limb bud organ cultures, in which they co-localised with Na, 
K-ATPase and epithelial Na+ channels in putative mechanoreceptor complexes [38]. These 
initial results were verified by analysing subunit-specific expression of L- and T-type VDCCs 
during cartilage and bone formation in mice [39]. According to these observations, intense 
immunoreactive signals for CaV1.2 (L-type) and CaV3.2 subunits (T-type) were visible along 
the perichondrium and in the growth plate at embryonic stage E14.5. At later stages (E18.5), 
CaV1.2 and CaV3.2 immunopositivity could still be observed in chondrocytes in the 
hypertrophic zone. These findings were corroborated using the murine chondrogenic cell line 
ATDC5. 
Our group examined α1 subunit expression profiles in embryonic chicken limb bud-
derived chondrifying micromass cultures and identified members of L-type (CaV1.2 and 
CaV1.3); R-type (CaV2.3); and T-type (CaV3.1, CaV3.2, and CaV3.3) VDCCs [36], in a good 
agreement with previously published data. Although the above studies showed the presence of 
functional α1 subunits in mature or differentiating chondrocytes, CaV3.2 was the first α1 subunit 
identified as essential for tracheal chondrogenesis in mice; in mice lacking CaV3.2 channels, 
Sox9 expression was attenuated, accompanied by disturbed tracheal cartilage formation [40].  
 
Mechanical load is partly mediated by L-type VDCCs in chondrocytes 
Mechanotransduction pathways in chondrocytes are still incompletely understood, but 
there is a growing body of evidence that stretch-sensitive ion channels are involved in the 
process. To elucidate the contribution of Ca2+ channels in chondrocyte mechanotransduction 
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pathways, 10 μM nifedipine was applied during mechanical stimulation of a 3D chondrocyte 
culture system established from 17-day-old chicken sterna [32]. As mentioned previously, 
nifedipine completely abolished the enhanced proliferation and maturation of chondrocytes 
triggered by mechanical load, indicating that L-type Ca2+ channels play an important role in 
mechanosensation and mechanotransduction in chicken sternum-derived chondrocytes. 
When cyclic mechanical strain (7% or 12% elongation by a computer-driven vacuum-
operated unit) was applied on growth ring-derived chondrocytes obtained from ribs of four-
week-old male rats [41], pre-incubation with nifedipine (at 10 μM) for 1 h before the strain was 
applied completely eliminated the strain-induced upregulation of parathyroid hormone related 
peptide (PTHrP), an important mediator of endochondral bone formation. These results 
supported the crucial function of VDCCs in mechanotransduction pathways. 
Continuing this line of research, another group analysed how ion channel inhibitors, 
most importantly nifedipine, influenced the effects of static and dynamic compression in 3D 
bovine articular cartilage explants [42]. They observed that inhibition of VDCCs by nifedipine 
affected total protein synthesis more prominently than GAG synthesis, and concluded that a 
rather complex signalling process, including ion channels, may regulate mechanical loading-
induced GAG production. To further scrutinise the potential role of VDCCs during cyclic 
mechanical compression, the ion channel regulation of cell spreading and retraction was 
studied in bovine chondrocytes [43]. Although nifedipine did not interfere with cell spreading 
immediately following mechanical compression, it prevented retraction compared to untreated 
control cells 6 h after stimulation, suggesting the involvement of VDCCs in regulating transient 
changes in cell shape. These findings led the authors to hypothesize that L-type VDCCs and 
α5β1 integrin, together with its associated Src kinase, form mechanoreceptor complexes that 
are involved in mechanosensation and mechanotransduction. As described earlier, a similar 
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hypothesis has been proposed that β1 integrins, VDCCs, and other ion channels form functional 
mechanoreceptor complexes in embryonic mouse limb bud chondrocytes [38]. 
 
VDCCs are required for chondrogenesis 
During the complex process of chondrogenesis, Ca2+ signalling pathways play 
determining roles [9, 10]. In earlier studies, we detected rapid Ca2+ oscillations, in addition to 
long-term sustained changes in cytosolic Ca2+ levels, in chicken limb bud-derived 
chondrogenic micromass cultures [44]. As mentioned above, treatment of mouse embryonic 
limb bud-derived micromass cultures with nifedipine during the early stages of differentiation 
blocked chondrogenesis, implicating the role of L-type VDCCs during the process [24]. Our 
research group was the first to describe that differentiating chondrocytes in chicken micromass 
cultures express the α1 subunits of L-, R- and T-type VDCCs at both mRNA and protein levels; 
in particular, we detected mRNA transcripts encoding CaV1.2 and CaV1.3; CaV2.3; as well as 
CaV3.1, CaV3.2, and CaV3.3 VDCCs in complete agreement with previously published data 
(see [39]). We also reported that the L-type VDCCs play important roles in generating Ca2+ 
influx for oscillations, as nifedipine (10 μM) disrupted the regular pattern of repetitive calcium 
transients. Furthermore, VDCC blockade abrogated chondrogenesis and almost completely 
inhibited cell proliferation [36]. These results indicate that by mediating Ca2+ dependent 
signalling pathways in chondroprogenitor cells, L-type VDCCs may play a very important role 
during the initial stages of chondrogenesis.  
As mentioned before, the T-type CaV3.2 was the first VDCC shown to be indispensable 
for tracheal chondrogenesis both in vivo and in vitro [40]. These findings were substantiated 
by the fact that mice lacking CaV3.2 showed congenital tracheal stenosis; conversely, Cav3.2 
over-expression in ATDC5 cells augmented chondrogenesis. Presumably Ca2+ influx through 
CaV3.2 would activate the calcineurin/NFAT pathway, and regulate Sox9 during tracheal 
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chondrogenesis. However, it is unclear why only tracheal ring cartilage, but not other types of 
cartilage (e.g., articular cartilage), is affected in mice lacking functional CaV3.2; the authors 
suggested that CaV3.2 is predominantly expressed in tracheal cartilage but hardly detectable in 
the other cartilages. Since these assumptions would contradict previous observations by other 
groups (see [39], for example), further studies are required to clarify the specific role of VDCCs 
(and CaV3.2 in particular) in chondrogenesis. 
 
VDCCs in the context of OA pathogenesis 
OA, a debilitating, multifactorial degenerative joint disease, is a main cause of pain, 
disability, and loss of mobility among the elderly. OA is characterised by gradual degeneration 
of articular cartilage, synovial inflammation (synovitis), and alterations to the peri-articular and 
subchondral bone; therefore, OA can be regarded as a disease of the whole joint. The molecular 
pathogenesis of OA is still not fully understood, which poses limitations to the development of 
effective disease-modifying therapeutic approaches [45]. 
As an attempt to shed more light on the molecular and physiological background of OA 
pathogenesis, the effects of basic calcium phosphate (BCP) crystals, associated with a rare, 
destructive form of OA phenotype, were investigated on cytosolic Ca2+ levels and Ca2+ 
oscillations in bovine articular chondrocytes and cartilage explants [46]. Inorganic BCP 
crystals elevated intracellular Ca2+ concentrations, induced Ca2+ oscillations, and at the same 
time enhanced the rate of matrix degradation (i.e., augmented GAG release, and upregulated 
mRNA expression of MMP-3, ADAMTS-4 and ADAMTS-5). Furthermore, functional L-type 
VDCCs were required for the calcium phosphate crystal-induced Ca2+ oscillations to take 
place, as treatment with verapamil (1 μM) prevented the crystal-induced rise in cytosolic Ca2+ 
concentration. It must be noted, however, that the crystal-induced GAG release, rather than the 
upregulated mRNA expression of MMP-3, ADAMTS-4 and ADAMTS-5, was associated with 
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the increased cytosolic Ca2+ levels. Therefore, these results imply that by blocking VDCC 
function the deleterious effects of inorganic crystal-induced Ca2+ signals could be inhibited and 
thus the associated OA progression and severity might also be reduced. 
The above results corroborated previous in vivo data also indicating the involvement of 
VDCCs in OA. In these papers the effects of PD-0200347, an α2δ ligand of VDCCs that 
selectively blocks Ca2+ currents, were studied in the anterior cruciate ligament resection dog 
model of OA. PD-0200347 significantly reduced the progression of structural changes in 
cartilage by reducing MMP-13 and iNOS gene expression and inhibiting ERK1/2 activation 
via a Ras-independent but PKCα-dependent mechanism [47, 48]. Taken together, these results 
suggest that VDCC-related Ca2+ signalling may be an important pathway involved in the 
pathogenesis of OA and that selective modulation and targeting of VDCC function might be 
beneficial for treating OA. 
In a recent paper, a drug repositioning strategy was deployed to screen for already 
approved drugs that induce FRZB expression (a soluble antagonist of Wnt signalling) and 
subsequently downregulate the Wnt/β-catenin pathway in human OA chondrocytes [49]. 
Verapamil, but not other Ca2+ channel blockers, upregulated FRZB gene expression and also 
stimulated chondrogenic marker gene (ACAN, COL2A1, SOX9) transcript levels. At the same 
time, verapamil reduced MMP3 expression. Furthermore, intra-articular injection of verapamil 
halted OA progression and ameliorated cartilage damage in knee joints in a rat OA-model [49]. 
Verapamil also inhibited hyaluronan export from IL-1β treated chondrocytes by blocking the 
ABC transporter MRP5, and prevented the loss of aggrecan in osteoarthritic rat knee joints [50, 
51]. However, since the inhibitory concentrations of verapamil that would be effective on the 
MRP5 transporter can never be reached in the serum using therapeutic and orally administered 
drug doses, an alternative hypothesis was suggested; the recent discovery that concurrent K+ 
efflux through Ca2+ activated Kir channels are required for hyaluronan export through MRP5 
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[52] suggest that blocking VDCC function and subsequent Ca2+ influx may inhibit K+ efflux 
and, simultaneously, excessive hyaluronan export. This hypothesis has yet to be validated. 
 
Clinical data on the effects of VDCC inhibitors in OA patients 
Various types of VDCCs are located throughout the human body participating in a wide 
range of functions. L- and T-type VDCCs are integral parts of the cardiovascular system and 
their over-activation could manifest in hypertension or arrhythmias; thus, they are the preferred 
targets of currently marketed calcium channel antagonists. Amongst the less frequent adverse 
effects of these medications, joint pain or arthralgia has been reported, but the frequency 
ranging from 0.5% to 3% does not differ significantly from that for placebo [53]. However, 
there are few studies available on the clinical outcome of calcium antagonists in joint pain, and 
collectively the evidence currently available is not convincing. 
There are some case reports on individual patients with hypertension who developed 
muscle and joint pain whilst taking antihypertensive medication (i.e., diltiazem hydrochloride, 
or amlodipine); on discontinuation of these drugs the muscle and joint symptoms were resolved 
[53, 54]. In a multicentre, randomized, double-blind clinical trial with a 10-week treatment 
period that compared the effects of controlled-onset extended release verapamil (314 mg/day) 
with a conventional, gastrointestinal nifedipine therapy (64 mg/day), arthralgia was more 
frequent in the nifedipine group (6%) than in the verapamil group (2%); and the difference was 
statistically significant (p=0.048) [55]. However, increased frequencies of joint pain have not 
been reported in other studies [56]. It must be noted however that (1) some of these cases are 
probably individual occurrences of joint pain caused by the medications; and (2) arthralgia is 
a broad term that refers to joint pain and does not necessarily imply pain that is directly evoked 
by OA. In the clinical papers discussed above, no direct evidence was collected regarding the 
specific cause and the mechanism for joint pain. 
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As discussed in the previous section, the severity of experimental OA may be 
ameliorated using a VDCC inhibitor that selectively blocks Ca2+ currents [48]. In a recently 
conducted survey using the standardised Lequesne questionnaire, the severity of OA in 
osteoarthritic patients receiving calcium antagonists for the treatment of cardiac arrhythmia 
was investigated. This study reports that long-term treatment with currently used medications 
such as Adalat® (active ingredient, nifedipine), Amlodipine® (amlodipine), Carmen® 
(lercanidipine), Nitrendipine® (nitrendipin), and Norvasc® (amlodipine) led to improvements 
of OA severity, at least based on subjective patient feedback and Lequesne scores, compared 
to control patients (who were not taking calcium antagonists) [57]. However, that study has 
major limitations that must to be taken into account. Firstly, patients in this study received co-
medication. Secondly, patients were not randomized for the study; there were notable 
differences in the demographics between the groups; and no power analysis was performed. 
Thirdly, a heterogenous group of calcium antagonists was included in the study. Finally, there 
is no evidence that antihypertensive drugs actually ameliorated the symptoms of OA in these 
patients; it might also be the case that the subjective disease improvement experienced by 
patients could have been caused by the desensitizing effects of Ca2+ antagonists on synovial 
nerve endings. 
 
Conclusions and future directions 
As it is now evident from data published in vitro and in vivo and summarised above, 
VDCCs are clearly important modulators of various functional aspects of chondrocyte 
physiology in health and disease, as well as during primary and terminal chondrocyte 
differentiation during pre- and post-natal growth plate development (i.e., chondrogenesis and 
endochondral bone formation). However, it is also evident that there are controversies and 
unresolved questions regarding their specific roles in chondrocytes from different sources (both 
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in terms of species and tissues of origin) and developmental stages. Depending on the 
experimental conditions applied, high concentrations of L-type VDCC blockers exert moderate 
to severe adverse effects on various signalling pathways, proliferation, growth and 
differentiation potential of chondrocytes both in vitro and in vivo, according to the literature 
reviewed here. These effects on chondrocytes from various sources analysed in diverse 
experimental conditions are summarised in Table 2. 
It must be noted, however, that some of the effects of the VDCC inhibitors, nifedipine 
or verapamil, on bone growth [23], or chondrogenic nodule formation in micromass cultures 
[24] could have been caused by non-specific effects of long-term exposure (more than 7 days) 
to supraphysiological concentrations (up to 100 μM) of the drug. Such concentrations may 
never be achieved in vivo via oral administration of nifedipine and verapamil. Although the 
half-maximal concentrations of L-type Ca2+ channel antagonists have been described in the 
range of 20 nM to 50 μM, these values vary considerably in different cell types [58]. 
Concentrations higher than 50 μM are likely to block other calcium entry pathways, or even 
non-specifically block Na+ and K+ channels; verapamil can also inhibit T-type channels even 
at intermediate concentrations [18, 58], or the ABC transporter MRP5 involved in hyaluronan 
export [51]. Given that the concentration of drug that actually reaches the chondrocyte within 
the articular cartilage of patients receiving medication for unrelated conditions (e.g., 
hypertension or arrhythmia) is as yet unknown, it is impossible to extrapolate from the in vitro 
data that is currently available. 
Whilst the effects of VDCC blockage with supraphysiological concentrations of 
nifedipine and verapamil in healthy chondroblasts and chondrocytes are mostly deleterious as 
they include inhibition of proliferation, ECM synthesis, or chondrogenic differentiation, 
VDCCs and their inhibitors (mainly verapamil) appear to play contrasting roles in 
inflammatory OA chondrocytes. This may hold promise for the development of novel 
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therapeutic approaches, possibly even through drug retargeting approaches. However, the 
effects of verapamil on OA chondrocytes might also be attributable to other, non-specific 
targets of the drug, which need to be taken into account. 
There are a few possible explanations for the observed differences in healthy and OA 
chondrocytes in terms of the effects of VDCC inhibitors and VDCC function. Firstly, healthy 
and OA chondrocytes have an altered complement of plasma membrane ion channels and 
porins, which can at least partially be attributed to ECM degradation during OA. In particular, 
a set of ion channels including Ca2+ activated potassium channels (BK and IK), Ca2+ activated 
Cl– channels, aquaporin-1 (AQP1), as well as voltage-gated K+ channels or the piezo-type 
mechanosensitive ion channel 2 (Piezo2) were differentially expressed in healthy vs. OA 
cartilage [59-61]. Most of these channels play important roles in setting the RMP. Some of 
them are also involved in chondrocyte volume regulation [62]. Secondly, as a consequence of 
altered ion channel expression and function, the RMP values in healthy and inflammatory OA 
chondrocytes are probably different. The RMP in freshly isolated canine (and also equine, 
ovine, and bovine) chondrocytes was much less negative compared to that of excitable cells 
[62]; this is of critical importance for the function of voltage-dependent Ca2+ channels – most 
importantly, T-type VDCCs. These channels are small-conductance, low voltage-activated 
channels [63], which may play a role in sustained Ca2+ entry in chondrocytes. It must be noted, 
however, that chondrocyte RMP values available in the literature may not reflect the actual 
“physiological” values because of inappropriately chosen experimental conditions - it is 
impossible to know if isolated and cultured chondrocytes will have the same RMP as 
chondrocytes in situ. Thirdly, based on the above, OA chondrocytes may be characterised by 
altered intracellular calcium homeostasis and linked Ca2+ dependent signalling pathways, 
adding a level of complexity to the picture. Clearly, future studies have to incorporate 
innovative experimental designs to address these possibilities. 
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As discussed earlier, our current understanding of VDCCs and the effects of the most 
widely used inhibitors in chondrocyte biology is limited and controversial, mainly because 
there are very few papers published in this specific area. It should also be added that studies 
showing no action of VDCC inhibitors in OA patients may have remained unpublished. To 
resolve the apparent contradictions, and to better understand the mechanism of VDCC function 
in different in healthy and OA chondrocytes, new basic and clinical studies should be 
conducted using physiologically and pharmacologically relevant concentrations of VDCC 
blockers with clearly defined endpoints, including a) a systematic and comprehensive analysis 
of VDCC subunit expression and function in various models; b) more representative in vitro 
models to enable a more specific identification of cellular and physiological targets of the 
inhibitors; and c) sensitive biomarkers that predict responses to the drugs [64, 65]. Besides 
providing a better understanding of chondrocyte biology in health and disease, these 
prospective studies may also lead to the development of novel approaches for improving 
articular cartilage bioengineering [66]. 
Paracelsus the ‘father’ of toxicology wrote: ‘All things are poison and nothing (is) 
without poison; only the dose makes that a thing is no poison.’ Clearly, it is the concentration 
that makes a drug toxic. Therefore, new preclinical and clinical studies to determine the 
therapeutic vs. deleterious doses of calcium-channel blockers such as nifedipine and verapamil 
are crucially needed. 
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This paper discusses the value of biomarkers in drug development for OA. In addition to being 
diagnostic and prognostic tools, biomarkers have utility as surrogate endpoints in clinical 
trials (efficacy of intervention).  
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Tables 
 
Table 1. Classification of VDCCs based on their α1 subunits and inhibitors. 
Superfamily Family α1 subunit Gene Pharmacology 
High 
Voltage 
Activated 
L 
CaV1.1 CACNA1S 
Dihydropyridines (nifedipine); 
phenyl-alkylamines (verapamil); 
calciseptine 
CaV1.2 CACNA1C 
CaV1.3 CACNA1D 
CaV1.4 CACNA1F 
N CaV2.1 CACNA1A ω-conotoxins 
P/Q CaV2.2 CACNA1B ω-agatoxins 
Intermediate 
Voltage 
Activated 
R 
CaV2.3 CACNA1E 
SNX-482 
Low Voltage 
Activated 
T 
CaV3.1 CACNA1G 
No selective inhibitor discovered 
to date 
CaV3.2 CACNA1H 
CaV3.3 CACNA1I 
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Table 2. Effects of nifedipine and/or verapamil on chondrocytes at different developmental 
stages and under different experimental conditions. 
 Effect(s) of 
Nifedipine and/or 
Verapamil 
Experimental 
Conditions 
Reference Notes 
1 Digital defects in 
rabbit foetuses  
40–100μmol/kg 
nifedipine 
administered to 
rabbits per os on day 
16 
[20], [21] Effects were attributed 
to decreased utero-
placental blood flow. 
2 No effect on Ca2+ 
signalling;  
high [K+] failed to 
evoke Ca2+ 
transients 
Bovine articular 
chondrocytes 
[22] Nifedipine did not 
interfere with Ca2+ 
oscillations evoked by 
ET or PDGF.* 
3 Influence epiphyseal 
growth plate and bone 
remodelling 
6 mg/kg/day 
nifedipine 
administered IV twice 
daily to growing 
rabbits 
[23]  
4 Nifedipine/verapamil 
inhibit 
chondrogenesis at 
early stages of 
differentiation 
Mouse embryonic 
limb bud-derived 
micromass cultures 
[24]  
5 Nifedipine/verapamil 
abrogate stimulatory 
effect of PGE2 on 
IGFBP-3 
High density primary 
cultures of human 
articular chondrocytes 
[25]  
6 IGF-1 and insulin 
evoke Ca2+ influx 
through L-type 
VDCCs 
Articular 
chondrocytes from 
21-day-old rabbits; 1 
μM verapamil 
[26]  
7 Unable to block high 
K+ evoked Ca2+ 
transients 
Chicken growth 
plate chondrocytes; 
nifedipine was used 
at 100 μM 
[27] BAY K 8644 had no 
effect; results indicate 
N-type channels. 
8 Eliminate positive 
effects of 
capacitatively coupled 
electric field 
Bovine articular 
chondrocytes; 40μM 
verapamil 
[28]  
9 Prevents PKC 
activation 
downstream of DTH 
signalling 
Male resting zone 
growth plate 
chondrocytes from 
rats; 10μM nifedipine 
[29] Ca2+ release from 
internal stores was also 
involved in the pathway. 
10 Verapamil stimulate 
3H-thymidine uptake 
and  
High density porcine 
articular chondrocyte 
cultures; 40 or 
80μg/mL verapamil 
[31]  
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11 Abolish enhanced 
proliferation rate 
caused by cyclic 
mechanical load 
Chicken sternum-
derived chondrocytes 
on 3D collagen 
scaffoldings; 10μM 
nifedipine 
[32]  
12 Verapamil reduced 
RMP by 18% and 
suppressed 
proliferation 
Human chondrocytes 
isolated form OA 
knee cartilage 
[33], [34] Longer incubation with 
verapamil was 
cytotoxic. 
13 Influence on 
endochondral 
ossification and 
proliferation in foetal 
rat metatarsal 
rudiments 
Rat epiphyseal 
growth plate 
chondrocytes; 10-
100μM verapamil 
[35]  
14 Disrupts regular 
pattern of calcium 
oscillations; abrogates 
chondrogenesis; 
almost completely 
blocks cell 
proliferation 
Chicken embryonic 
limb bud-derived 
micromass cultures 
[36]  
15 Completely 
eliminates the strain-
induced upregulation 
of PTHrP 
Cyclic mechanical 
strain on growth ring-
derived chondrocytes 
from ribs of four-
week-old male rats; 
10 μM nifedipine 
[41]  
16 Nifedipine more 
prominently affects 
protein synthesis 
compared to GAG 
synthesis 
Static and dynamic 
compression in 3D 
bovine articular 
cartilage explants 
[42]  
17 Prevents retraction 
after mechanical 
stimulation 
Mechanical 
compression of 
bovine chondrocytes; 
nifedipine was used at 
10 μM 
[43] Nifedipine did not 
interfere with cell 
spreading. 
 
Note: Entries in boldface typesetting (lines 2 and 7) report negative results (i.e., implicate no 
function of VDCCs and/or their inhibitors) 
 
 
